The discovery, development, manufacturing, delivery, and sales of specialty pharmaceuticals require new and advanced tools, technologies, and expertise. While these structural changes present significant challenges to traditional pharmaceutical manufacturers to comply with new health regulations, they also present opportunities for a variety of stakeholders from biotechnology and diagnostics companies to new entrants, such as third party logistic providers, packaging manufacturers, health economics, information technology, and telecommunications firms.